%0 Multicenter Study
%T Serum S-100B adds incremental value for the prediction of symptomatic intracranial hemorrhage and brain edema after acute ischemic stroke.
%A Honegger T
%A Schweizer J
%A Bicvic A
%A Westphal LP
%A Schütz V
%A Inauen C
%A Pokorny T
%A Bracher K
%A Arnold M
%A Fischer U
%A Bonati LH
%A De Marchis GM
%A Nedeltchev K
%A Kahles T
%A Cereda C
%A Kägi G
%A Montaner J
%A Bustamante A
%A Palà E
%A Ntaios G
%A Foerch C
%A Luft A
%A Spanaus K
%A Saleh L
%A von Eckardstein A
%A Arnold M
%A Katan M
%J Eur Stroke J
%V 8
%N 1
%D 03 2023
%M 37021149
%F 5.894
%R 10.1177/23969873221145391
%X Early identification of patients developing symptomatic intracranial hemorrhage and symptomatic brain edema after acute ischemic stroke is essential for clinical decision-making. Astroglial protein S-100B is a marker of blood-brain barrier disruption, which plays an important role in the formation of intracranial hemorrhage and brain edema. In this study, we assessed the prognostic value of serum S-100B for the development of these complications.<BR>Serum S-100B levels were measured within 24 h from symptom onset in 1749 consecutive acute ischemic stroke patients from the prospective, observational, multicenter BIOSIGNAL cohort study (mean age 72.0 years, 58.3% male). To determine symptomatic intracranial hemorrhage or symptomatic brain edema, follow-up neuroimaging was performed in all patients receiving reperfusion therapy or experiencing clinical worsening with an NIHSS increase of ⩾4.<BR>Forty six patients (2.6%) developed symptomatic intracranial hemorrhage and 90 patients (5.2%) developed symptomatic brain edema. After adjustment for established risk factors, log10S-100B levels remained independently associated with both symptomatic intracranial hemorrhage (OR 3.41, 95% CI 1.7-6.9, p = 0.001) and symptomatic brain edema (OR 4.08, 95% CI 2.3-7.1, p < 0.001) in multivariable logistic regression models. Adding S-100B to the clinical prediction model increased the AUC from 0.72 to 0.75 (p = 0.001) for symptomatic intracranial hemorrhage and from 0.78 to 0.81 (p < 0.0001) for symptomatic brain edema.<BR>Serum S-100B levels measured within 24 h after symptom onset are independently associated with the development of symptomatic intracranial hemorrhage and symptomatic brain edema in acute ischemic stroke patients. Thus, S-100B may be useful for early risk-stratification regarding stroke complications.